List view / Grid view
Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.
In this Q&A, Dr Murray Cairns, NHMRC Leadership Research Fellow at the University of Newcastle, shares his insights about the genetic influences on circulating retinol, and explains how a retinol polygenic score could be utilised in a precision medicine approach.
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
Having resolved the structure of psychedelic drugs bound to the 5-HT2A serotonin receptor researchers are now developing new therapeutic drugs.
Researchers have conducted promising preclinical experiments on a compound that could be used to treat Wilson's disease...
